Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Several grading systems have been developed in the bone marrow transplantation setting in attempts to predict survival in patients with chronic graft-versus-host disease (cGVHD). In this study, we evaluated the prognostic value of the National Institutes of Health (NIH) scoring system and investigated for any additional prognostic factors in a series of 171 patients undergoing peripheral blood stem cell transplantation (PBSCT) from matched related donors. The cumulative incidence of cGVHD was 70%; cumulative incidences of mild, moderate, and severe cGVHD were 29%, 42% and 28%, respectively. Overall, 68% of patients were free from immunosuppression 5 years after transplantation. Absence of previous acute GVHD (aGVHD; hazard ratio [HR] = 2; P = .004) and mild cGVHD (HR = 4.2; P = .007) increased the probability of being off immunosuppressive treatment by the last follow-up. Overall survival (OS) at 5 years was 52%. Severe cGVHD, according to the NIH scoring system (HR = 13.27; P = .001) adversely influenced outcome, whereas de novo onset (HR = 0.094; P = .003) had a more favorable impact on survival. The combination of both variables allowed us to identify 4 different subgroups of patients with OS of 82%, 70%, 50%, and 25%. Our findings indicate that the NIH scoring system has some prognostic value in patients undergoing PBSCT and, together with the type of onset, must be considered to predict the possible outcome of patients who develop cGVHD.
Pérez-Simón
José A
JA
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain. Electronic address: pesimo@usal.es.
Encinas
Cristina
C
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Silva
Fernando
F
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Arcos
Maria José
MJ
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Díez-Campelo
María
M
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Sánchez-Guijo
Fermín M
FM
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Colado
Enrique
E
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Martín
Jesús
J
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Vazquez
Lourdes
L
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Del Cañizo
Consuelo
C
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
Caballero
Dolores
D
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
San Miguel
Jesús
J
Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
D017677:Age Distribution; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000401:mortality*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008107:Liver Diseases / Q000175:diagnosis; D008171:Lung Diseases / Q000175:diagnosis; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate
D007166:Immunosuppressive Agents